Can early interventions such as daily low‑dose phosphodiesterase‑5 inhibitors (tadalafil or sildenafil), vacuum erection device use, and intracavernosal alprostadil injections permanently preserve erectile function?

No, These Interventions Do Not Permanently Preserve Erectile Function

Early interventions with daily low-dose PDE5 inhibitors, vacuum erection devices, and intracavernosal alprostadil do not permanently restore or preserve unassisted erectile function—they provide symptomatic treatment that requires ongoing use to maintain benefit. 1

The Evidence on "Penile Rehabilitation"

The concept of penile rehabilitation after prostate cancer treatment has been extensively studied, particularly with PDE5 inhibitors. The 2018 AUA Guideline explicitly states that "trials have not demonstrated that early PDE5i use (i.e., within 45 days of prostate cancer therapy) improves unassisted erectile function" 1. While these medications are effective at assisting erections on-demand during treatment, they do not create lasting improvement once discontinued.

What the Research Shows:

• PDE5 inhibitors work symptomatically: They facilitate erections during sexual activity by enhancing blood flow, but this effect is temporary and medication-dependent 1, 2

• Vacuum erection devices (VED) may help preserve penile length and girth when used early after radical prostatectomy 3, 4, and some data suggests improved natural erection rates at 5 years with early prophylactic use 4. However, this represents maintenance of tissue health rather than permanent restoration of function

• Intracavernosal alprostadil provides effective symptomatic treatment but requires ongoing injections 5, 6

The Mechanism Explains the Limitation

These interventions work through different mechanisms:

• PDE5 inhibitors enhance nitric oxide signaling to improve blood flow during sexual stimulation
• VED mechanically draw blood into the penis
• Alprostadil directly relaxes smooth muscle in the corpora cavernosa

None of these mechanisms reverse the underlying structural damage to nerves, blood vessels, or smooth muscle tissue that causes erectile dysfunction after prostate cancer treatment 5. They compensate for dysfunction rather than cure it.

What "Rehabilitation" Actually Means

The term "penile rehabilitation" is somewhat misleading. What these interventions may accomplish is:

• Maintaining tissue oxygenation through regular erections, potentially preventing further deterioration 7
• Preserving penile dimensions (length and girth) that might otherwise be lost 3, 4
• Supporting cavernosal tissue health during the recovery period 7

This is tissue preservation, not functional restoration. Once you stop the intervention, the erectile assistance stops.

Clinical Reality

In long-term follow-up studies of post-prostatectomy patients using early VED therapy, 71% had natural erections sufficient for intercourse at 5 years—but notably, many continued using the VED or required sildenafil 4. The "natural" erections occurred in the context of ongoing rehabilitation protocols, not after stopping treatment.

The Bottom Line for Your Patient

You should counsel patients that:

1. These interventions require ongoing use to maintain erectile function
2. Stopping treatment typically means losing the benefit
3. The goal is functional erections with assistance, not cure
4. Early intervention may prevent further deterioration and preserve penile tissue health, which is valuable but different from permanent restoration
5. Combination approaches (PDE5i plus alprostadil) may be more effective than monotherapy for refractory cases 8, but still require continued use

The most honest framework is that these are chronic management strategies, not curative interventions. They enable sexual function but do not permanently restore the erectile mechanism damaged by cancer treatment.